Form 10-Q · Quarterly report
IDEX Corporation 10-Q, filed Jul 29, 2026
- Filed
- CIK
- 0000832101
- Accession no.
- 0000832101-26-000022
Summary
IDEX Corporation reported second-quarter 2026 net sales of $920.6 million, up 6% overall and 5% organically, and diluted EPS of $1.93, up 11%, after collecting substantially all anticipated refunds of tariffs invalidated by the U.S. Supreme Court under the International Emergency Economic Powers Act. The refunds reduced cost of sales by $22.0 million and net sales by $14.7 million for expected customer rebates, while the Health & Science Technologies segment drove organic growth on AI-related data center and semiconductor demand.
Key points
- IDEX's second-quarter net sales rose 6% to $920.6 million and diluted EPS rose 11% to $1.93.
- IDEX collected substantially all anticipated IEEPA tariff refunds during Q2 2026, reducing cost of sales by $22.0 million and net sales by $14.7 million for expected customer rebates.
- The Health & Science Technologies segment's net sales increased 14% to $415.0 million, driven by AI-related data center power and semiconductor demand, space and defense, and positive price.
- IDEX repurchased $77.1 million of shares and paid $53.9 million of dividends in Q2 2026.
Written by an AI model from the filing text. It can be incomplete or wrong; the filing on SEC.gov is the record.
From the filing
Item 2. Management’s Discussion Overview IDEX is an applied solutions provider specializing in the manufacturing of health and science technologies, fluid and metering technologies, and fire, safety and other diversified products built to customers’ specifications. IDEX’s products are sold in niche markets across a wide range of industries throughout the world. Accordingly, IDEX’s businesses are affected by levels of industrial activity and economic conditions in the U.S. and in other countries where it does business, as well as by the relationship of the U.S. Dollar to other currencies. …
An excerpt of the text as filed with the SEC, cut for length.
Readster writes AI-generated summaries of public filings for research purposes only. Summaries can be incomplete or wrong — check the original filing on SEC.gov before relying on it. Nothing here is investment, legal or medical advice.